Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The Institute for Clinical and Economic Review developed an evidence report, including a systematic review of the literature, a cost-effectiveness model, and a budget impact assessment, to support a public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) on October 27, 2015.1 The report evaluates the comparative clinical effectiveness and comparative value of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as a class for the treatment of adults with familial hypercholesterolemia or cardiovascular disease (CVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.
Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol LevelsEffectiveness and Value. JAMA Intern Med. 2016;176(1):107-108. doi:10.1001/jamainternmed.2015.7248